Combinatorial fedratinib and venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high Flt3 expression

Treatment of relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) remains a challenge, particularly in patients who do not respond to traditional chemotherapy or immunotherapy. The objective of this study was to assess the efficacy of fedratinib, a semi selective JAK2 inhibitor and veneto...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinella, Sean P, Bell, Haley C, Turicek, David P, Shi, Lei, Hoang, Nguyet-Minh, Rui, Lixin, Hess, Nicholas J, Capitini, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274796/
https://www.ncbi.nlm.nih.gov/pubmed/37333339
http://dx.doi.org/10.1101/2023.06.07.544058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274796/
https://www.ncbi.nlm.nih.gov/pubmed/37333339
http://dx.doi.org/10.1101/2023.06.07.544058

Ejemplares similares